☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Hepcludex
Gilead Presented P-III Trial (MYR301) Results of Hepcludex (bulevirtide) for Chronic Hepatitis Delta Virus at EASL 2023
June 24, 2023
Gilead’s Hepcludex (bulevirtide) Receives NICE Recommendation for the Treatment of Chronic Hepatitis Delta Virus Infection
May 16, 2023
Gilead Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Hepcludex (bulevirtide) for Hepatitis Delta Vi...
May 5, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.
